Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) on November 2 and set a price target of $138.00. The company’s shares closed yesterday at $105.42.
According to TipRanks, Johnson is a 5-star analyst with an average return of 17.1% and a 53.44% success rate. Johnson covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Align Tech, and Cooper Co.
Zimmer Biomet Holdings has an analyst consensus of Hold, with a price target consensus of $121.22, which is a 14.99% upside from current levels. In a report released yesterday, JMP Securities also maintained a Buy rating on the stock with a $145.00 price target.
ZBH market cap is currently $22.6B and has a P/E ratio of 81.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.
Read More on ZBH:
- Zimmer Biomet Announces Third Quarter 2022 Financial Results
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Barclays starts medical devices with Positive view, Boston Scientific top pick
- Zimmer Biomet initiated with an Underweight at Barclays
- Zimmer Biomet initiated with an Underperform at Jefferies